source
- Regeneron Ventures leads $75 million Series A for eczema-focused antibody startup InfinimmuneInfinimmune, a Bay Area biotech developing antibody therapies for eczema, announced a $75 million Series A financing round. The round was co-led by Regeneron Ventures and Playground Global, with p…
- Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 pushSobi has bought into Innate Pharma’s vision for lacutamab, handing the French biotech $75 million upfront for the rights to market the anti-KIR3DL2 antibody for an aggressive skin cancer.